163 related articles for article (PubMed ID: 37204204)
1. Predictive markers for pathological complete response (pCR) after neo-adjuvant chemotherapy in HER2-positive breast carcinoma.
Van Bockstal MR; Dano H; Benhaddi N; Dubois D; Vanderveken J; Van Marcke C; Vandermeulen A; Duhoux FP; Vernaeve H; Berlière M; Galant C
Histol Histopathol; 2024 Feb; 39(2):153-164. PubMed ID: 37204204
[TBL] [Abstract][Full Text] [Related]
2. Triple-Positive Breast Carcinoma: Histopathologic Features and Response to Neoadjuvant Chemotherapy.
Zeng J; Edelweiss M; Ross DS; Xu B; Moo TA; Brogi E; D'Alfonso TM
Arch Pathol Lab Med; 2021 Jun; 145(6):728-735. PubMed ID: 33112958
[TBL] [Abstract][Full Text] [Related]
3. Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.
Li AC; Zhao J; Zhao C; Ma Z; Hartage R; Zhang Y; Li X; Parwani AV
Breast Cancer Res Treat; 2020 Apr; 180(2):321-329. PubMed ID: 32002765
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma.
Peng JH; Zhang X; Song JL; Ran L; Luo R; Li HY; Wang YH
Medicine (Baltimore); 2019 Jan; 98(2):e13554. PubMed ID: 30633152
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
Kinsella MD; Nassar A; Siddiqui MT; Cohen C
Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
[TBL] [Abstract][Full Text] [Related]
6. HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer.
Zhao J; Krishnamurti U; Zhang C; Meisel J; Wei Z; Suo A; Aneja R; Li Z; Li X
Pathol Res Pract; 2020 Nov; 216(11):153155. PubMed ID: 32871536
[TBL] [Abstract][Full Text] [Related]
7. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
Krystel-Whittemore M; Xu J; Brogi E; Ventura K; Patil S; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
Breast Cancer Res Treat; 2019 Aug; 177(1):61-66. PubMed ID: 31144151
[TBL] [Abstract][Full Text] [Related]
8. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer.
Wang Y; Singh K; Dizon D; Graves T; Amin A; Yakirevich E
Breast Cancer Res Treat; 2021 Apr; 186(3):667-676. PubMed ID: 33598878
[TBL] [Abstract][Full Text] [Related]
10. MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.
Calhoun BC; Portier B; Wang Z; Minca EC; Budd GT; Lanigan C; Tubbs RR; Morrison LE
BMC Cancer; 2016 Aug; 16(1):695. PubMed ID: 27576528
[TBL] [Abstract][Full Text] [Related]
11. Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy.
Osako T; Horii R; Matsuura M; Ogiya A; Domoto K; Miyagi Y; Takahashi S; Ito Y; Iwase T; Akiyama F
J Cancer Res Clin Oncol; 2010 Feb; 136(2):233-41. PubMed ID: 19685074
[TBL] [Abstract][Full Text] [Related]
12. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.
Meisel JL; Zhao J; Suo A; Zhang C; Wei Z; Taylor C; Aneja R; Krishnamurti U; Li Z; Nahta R; O'Regan R; Li X
Clin Breast Cancer; 2020 Feb; 20(1):19-24. PubMed ID: 31806448
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?
Xian Z; Quinones AK; Tozbikian G; Zynger DL
Hum Pathol; 2017 Apr; 62():215-221. PubMed ID: 28041972
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.
Al-Saleh K; Salah T; Arafah M; Husain S; Al-Rikabi A; Abd El-Aziz N
PLoS One; 2021; 16(3):e0247802. PubMed ID: 33667252
[TBL] [Abstract][Full Text] [Related]
16. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
17. Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB).
Greenwell K; Hussain L; Lee D; Bramlage M; Bills G; Mehta A; Jackson A; Wexelman B
Breast Cancer Res Treat; 2020 Jun; 181(2):249-254. PubMed ID: 32277375
[TBL] [Abstract][Full Text] [Related]
18. Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration.
Zhou X; Zhang J; Yun H; Shi R; Wang Y; Wang W; Lagercrantz SB; Mu K
Oncotarget; 2015 Nov; 6(34):36894-902. PubMed ID: 26384297
[TBL] [Abstract][Full Text] [Related]
19. [Changes of immunohistochemical biomarkers before and after neoadjuvant chemotherapy in breast cancer and their prognosis].
Sun MM; Jiang YN; Song GX; Zhuo SS; Zhang ZH
Zhonghua Bing Li Xue Za Zhi; 2021 May; 50(5):482-487. PubMed ID: 33915655
[No Abstract] [Full Text] [Related]
20. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
Robertson S; Rönnlund C; de Boniface J; Hartman J
Breast Cancer Res Treat; 2019 Apr; 174(3):795-805. PubMed ID: 30659433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]